Posted by Michael Wonder on 29 May 2017
Athersys announces fast track designation by FDA for stroke program and other progress
9 May 2017 - Athersys today announced its financial results for the three months ended 31 March 2017.
Highlights of the first quarter of 2017 and recent events include clinical program for stroke awarded fast track designation by the U.S. FDA.
Designation means that the program becomes eligible for rolling submission, accelerated approval and priority review of the biologics license application, facilitating timely regulatory review.
